C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CCCC)

CUSIP: 12529R107

Q1 2021 13F Holders as of 31 Mar 2021

Holder snapshot 6 signals
Share change
+2,390,297
SEC-reported price per share
$36.99
Number of holders
83
Value change
+$90,401,887
Number of buys
45
Number of sells
31
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
111,000,000

Security key

12529R107

Report period

Q1 2021

Institutions

83

Top holders

10

Ownership snapshot

Top reported holders of CCCC - C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
PERCEPTIVE ADVISORS LLC
Disclosed value leader
PERCEPTIVE ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Dec 2020
13F Lead comparable stake: 2.8% Showing 1-6 of 15 holder rows.

Quick read

PERCEPTIVE ADVISORS LLC leads the comparable SEC ownership view at 2.8%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens PERCEPTIVE ADVISORS LLC's linked filing trail.
Comparable ownership Top 5
PERCEPTIVE ADVISORS LLC 2.8%
Cormorant Asset Management, LP 2.2%
RTW INVESTMENTS, LP 1.9%
Bain Capital Life Sciences Invest... 1.5%
PRICE T ROWE ASSOCIATES INC /MD/ 1.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
PERCEPTIVE ADVISORS LLC
13F
Company
13F
2.8%
$104,643,000
3,158,566 shares
31 Dec 2020
Cormorant Asset Management, LP
13F
Company
13F
2.2%
$80,021,000
2,490,065 shares
31 Dec 2020
RTW INVESTMENTS, LP
13F
Company
13F
1.9%
$68,679,000
2,149,228 shares
31 Dec 2020
Bain Capital Life Sciences Investors, LLC
13F
Company
13F
1.5%
$54,406,000
1,642,209 shares
31 Dec 2020
PRICE T ROWE ASSOCIATES INC /MD/
13F
Company
13F
1.4%
$49,381,000
1,530,042 shares
31 Dec 2020
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
1.2%
$45,639,000
1,377,569 shares
31 Dec 2020
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2021

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
83
Shares
25,097,387
Rows available
83
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2021 vs Q4 2020 Across Filers

Q4 2020 holders
75
Q1 2021 holders
83
Holder diff
8
Investor Q4 2020 Shares Q1 2021 Shares Share Diff Share Chg % Q4 2020 value Q1 2021 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .